Tag: SNRS, PAIN, FAMI

By Robin Foster HealthDay Reporter FRIDAY, June 28, 2024 (HealthDay News) -- As a summer wave of COVID infections rolls across the country, U.S. health...

By Ernie Mundell HealthDay Reporter FRIDAY, June 28, 2024 (HealthDay News) -- The spread of H5N1 avian flu to dairy cows has health experts and...

89 percent of cancer centers report that cancer drugs are in short supply, most often vinblastine, etoposide, and topotecan

94 percent probability that intervention was cost-effective seen at a willingness-to-pay threshold of $28,000

Cesarean delivery accounts for highest proportion of MMEs dispensed after surgery among individuals aged 18 to 44 years

Positive and negative predictive values exceeded 95 percent for multitask large language model

Evidence seen for dose-response association, with 33 percent increased risk for one-unit lower cognitive function

Improvement in two-year progression-free survival seen with PGT versus standard of care or targeted agents not guided by molecular findings

Significantly lower risk of major adverse cardiovascular events, all-cause mortality seen in metabolic surgery group

Lower rate of disease-free survival and overall survival seen for minimally invasive versus open hysterectomy

Responses more frequent in initiators than noninitiators, but 40 to 50 percent of initiators did not meet response criteria

Tailored recommendations presented to maximize survival and minimize side effects

Individuals with consistently high loneliness patterns over time had significantly higher incident stroke risk

14 percent of patients with early rheumatoid arthritis had mono-, oligo-arthritis and PGA ≥50

By Robin Foster HealthDay Reporter FRIDAY, June 28, 2024 (HealthDay News) -- The U.S. Supreme Court on Thursday struck down a controversial settlement that drug...